Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. [caso clínico]
Por: Sevillano Prieto, Ángel Manuel [Nefrología]
| Hernández Martínez, Eduardo [Nefrología] | González Monte, Esther [Nefrología] | Mateo Bernardo, Isabel [Reumatología] | Gutiérrez Martínez, Eduardo [Nefrología] | Morales Ruiz, Enrique [Nefrología] | Praga Terente, Manuel [Nefrología].
Colaborador(es): Servicio de Nefrología | Servicio de Reumatología.
Tipo de material: 
ArtículoEditor: Nefrología : publicación oficial de la Sociedad Española Nefrologia, 2016Descripción: 36(1):63-6.Recursos en línea: Solicitar documento Resumen: Renal amyloidosis is one of the most severe complications of familial Mediterranean fever (FMF). Colchicine has reduced the incidence of this complication, which now only appears in untreated, under-treated and resistant patients, but it is usually ineffective in patients with advanced amyloidosis. Here we report a patient with FMF and biopsy-proven amyloidosis who presented with nephrotic syndrome despite colchicine treatment. Anakinra (an interleukin-1β inhibitor) was started and a dramatic complete remission of nephrotic syndrome was observed in the following months. Anakinra can be an effective treatment for FMF patients with severe secondary amyloidosis.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Caso clínico
|
PC17541 (Navegar estantería) | Disponible |
Formato Vancouver:
Sevillano ÁM, Hernandez E, Gonzalez E, Mateo I, Gutierrez E, Morales E, Praga M. Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. Nefrologia. 2016;36(1):63-6.
PMID: 26409501
Contiene 29 referencias
Renal amyloidosis is one of the most severe complications of familial Mediterranean fever (FMF). Colchicine has reduced the incidence of this complication, which now only appears in untreated, under-treated and resistant patients, but it is usually ineffective in patients with advanced amyloidosis. Here we report a patient with FMF and biopsy-proven amyloidosis who presented with nephrotic syndrome despite colchicine treatment. Anakinra (an interleukin-1β inhibitor) was started and a dramatic complete remission of nephrotic syndrome was observed in the following months. Anakinra can be an effective treatment for FMF patients with severe secondary amyloidosis.
No hay comentarios para este ejemplar.